In a murine model, the half-life of N106 is determined to be ～65.4min with a Cmax of ～2.24μM when the mice received 10mg/kg of N106 by intravenous injection. The oral bioavailability (F%) is 56% and 50%, and terminal elimination half-life (t1/2) is 19min[1].
In vivo, N106 (10 mg/kg) increases cardiac SERCA2A SUMOylation, and significantly improves ventricular function in mice with heart failure[1].
